About this trial
Chronic obstructive pulmonary disease (COPD) stands as one of the leading causes of mortality worldwide. Acute exacerbations of COPD (AECOPD) lead to rapid respiratory function decline and worsened disease status. Despite recent studies, the ability of the neutrophil-to-lymphocyte ratio (NLR) to predict outcomes in patients with COPD remains controversial. It remains controversial whether NLR can predict clinical outcomes in hospitalized patients with AECOPD. Therefore, this study was conducted to investigate the predictive value of NLR for severity, adverse outcomes in hospitalized patients with AECOPD, and predicting treatment response in patients with AECOPD
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 18 and above, Patients who will be admitted at the Chest department, Ain-Shams University Hospitals, diagnosed with AECOPD based on the Global Initiative for Chronic Obstructive Lung Disease 2024 criteria
Disqualifiers
Patients who refused treatment.
COPD patients with Malignancy, hematological disorders
Trial population
Patients aged 18 and above Patients who will be admitted at Chest department, Ain-Shams University Hospitals diagnosed with AECOPD based on the global initiative for chronic obstructive lung disease 2024 criteria
Trial design
Other
Cross-sectional
Treatments tested in this trial
neutrophil lymphocyte ratio in COPD patients
Other interventionNeutrophil lymphocyte ratio in determining severity and prognosis in exacerbation of COPD patients
Treatment groups
Trial outcomes
Primary outcomes
The ratio of neutrophils to lymphocytes in (%) in the CBC
investigate the relation between this % ratio and severity of symptoms and adverse hospitalization outcomes in hospitalized patients with AECOPD
Secondary outcomes
The ratio of neutrophils to lymphocytes in (%) in the CBC
\- investigate the relation between this % ratio and spirometric indices (FEV1, FVC) as percent predicted in hospitalized patients with AECOPD in their follow up
Sponsors and contacts
Click on the lead sponsor to view all of their trials.